Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

1.29
-0.0900-6.52%
Post-market: 1.300.0100+0.78%19:34 EDT
Volume:1.14M
Turnover:1.50M
Market Cap:171.57M
PE:-2.71
High:1.58
Open:1.39
Low:1.18
Close:1.38
52wk High:8.57
52wk Low:0.9200
Shares:133.00M
Float Shares:23.24M
Volume Ratio:0.42
T/O Rate:4.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4756
EPS(LYR):-21.5800
ROE:-318.04%
ROA:-98.08%
PB:15.09
PE(LYR):-0.06

Loading ...

Indaptus Therapeutics - Proposed Resale of up to 58,895,000 Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Aug 18

Indaptus Q2 Net Loss Narrows as Costs Fall

Reuters
·
Aug 13

Indaptus Therapeutics Q2 EPS USD -0.02

THOMSON REUTERS
·
Aug 13

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 13

Insider Traders Lose US$34k As Indaptus Therapeutics Drops

Simply Wall St.
·
Jul 08

Indaptus Therapeutics Inc - Files for Resale by the Selling Stockholders of up to 18.86 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 27

Indaptus Therapeutics - to Issue 20 Mln Shares at $0.6 Per Share - SEC Filing

THOMSON REUTERS
·
Jun 25

Indaptus Therapeutics - Private Placement Gross Proceeds About $12 Mln Before Expenses - SEC Filing

THOMSON REUTERS
·
Jun 25

Indaptus Therapeutics Sells 20,000,000 Shares at $0.6 in $12 Million Private Placement

Reuters
·
Jun 25

Top Premarket Decliners

MT Newswires Live
·
Jun 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:47 PM

Reuters
·
Jun 05

Indaptus Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 15

Indaptus net loss narrows to $2.5 million in Q1 FY26; R&D expenses drop 82% to $491,134

Reuters
·
May 15

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 15

Indaptus Therapeutics Q1 EPS USD -0.23

THOMSON REUTERS
·
May 15

Indaptus Therapeutics Inc expected to post a loss of $1.87 a share - Earnings Preview

Reuters
·
May 08

Indaptus amends 8-K to reflect director Johnny Fox Arrowsmith legal name change

Reuters
·
Apr 25

Indaptus Therapeutics director Qinglai Lu files initial beneficial ownership statement

Reuters
·
Apr 21

Indaptus Therapeutics Inc - Appoints Yu Ding as CFO Effective April 1, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 04

Indaptus Therapeutics names Yu Ding CFO after Nir Sassi resignation

Reuters
·
Apr 04